BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36188616)

  • 21. Effects of Wuzhi Capsule on Whole-Blood Tacrolimus Concentration Levels: A Systematic Review and Meta-Analysis.
    Zhang C; Ren X; Liu Y; Huang L; Feng Y; Zhang X
    Ther Drug Monit; 2024 Feb; 46(1):33-41. PubMed ID: 38150711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule.
    Chen X; Wang D; Xu H; Li Z
    J Clin Pharm Ther; 2020 Apr; 45(2):309-317. PubMed ID: 31755126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers.
    Tang HL; Xie HG; Yao Y; Hu YF
    Pharmacogenet Genomics; 2011 Nov; 21(11):713-20. PubMed ID: 21886016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization of initial dosing scheme of tacrolimus in pediatric refractory nephrotic syndrome patients based on CYP3A5 genotype and coadministration with wuzhi-capsule.
    Chen X; Wang DD; Xu H; Li ZP
    Xenobiotica; 2020 May; 50(5):606-613. PubMed ID: 31530218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association Between CYP3A5 Genetic Polymorphisms with Tacrolimus Dose Requirement and Allograft Outcomes in Iranian Kidney Transplant Recipients.
    Ghafari S; Dashti-Khavidaki S; Khatami MR; Ghahremani MH; Seyednejad SA; Beh-Pajooh A
    Iran J Kidney Dis; 2019 Nov; 13(6):414-416. PubMed ID: 31880588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients.
    Yanik MV; Seifert ME; Locke JE; Hauptfeld-Dolejsek V; Crowley MR; Cutter GR; Mannon RB; Feig DI; Limdi NA
    Pediatr Transplant; 2019 Aug; 23(5):e13494. PubMed ID: 31124575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.
    Chen SY; Li JL; Meng FH; Wang XD; Liu T; Li J; Liu LS; Fu Q; Huang M; Wang CX
    Clin Transplant; 2013; 27(3):E272-81. PubMed ID: 23432535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
    Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
    Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients.
    Fukudo M; Yano I; Masuda S; Goto M; Uesugi M; Katsura T; Ogura Y; Oike F; Takada Y; Egawa H; Uemoto S; Inui K
    Clin Pharmacol Ther; 2006 Oct; 80(4):331-45. PubMed ID: 17015051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Wuzhi capsule increased systemic exposure to methotrexate by inhibiting the expression of OAT1/3 and P-gp.
    Fu R; Wang XN; Guo CH; Li Y; Ding CY; Li YJ; Dong ZJ
    Ann Transl Med; 2021 May; 9(10):845. PubMed ID: 34164479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.
    Jacobo-Cabral CO; García-Roca P; Romero-Tejeda EM; Reyes H; Medeiros M; Castañeda-Hernández G; Trocóniz IF
    Br J Clin Pharmacol; 2015 Oct; 80(4):630-41. PubMed ID: 25846845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.
    Benkali K; Rostaing L; Premaud A; Woillard JB; Saint-Marcoux F; Urien S; Kamar N; Marquet P; Rousseau A
    Clin Pharmacokinet; 2010 Oct; 49(10):683-92. PubMed ID: 20818834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
    Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
    Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
    Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
    Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
    Wei-lin W; Jing J; Shu-sen Z; Li-hua W; Ting-bo L; Song-feng Y; Sheng Y
    Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Tacrolimus Starting Doses Based on CYP3A5 Phenotype or Genotype in Kidney Transplant Recipients.
    Largeau B; Guellec CB; Longuet H; Lesne P; Bouvarel A; Préteseille L; Marquet P; Halimi JM; Büchler M; Gatault P; Noble J
    Prog Transplant; 2019 Dec; 29(4):300-308. PubMed ID: 31514576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of CYP3A5 polymorphisms on tacrolimus pharmacokinetics in pediatric kidney transplantation: a systematic review and meta-analysis of observational studies.
    Zong YP; Wang ZJ; Zhou WL; Zhou WM; Ma TL; Huang ZK; Zhao CC; Xu Z; Tan RY; Gu M
    World J Pediatr; 2017 Oct; 13(5):421-426. PubMed ID: 28540692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of cytochrome P450 3A5 polymorphism on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Htun YY; Than NN; Swe HK
    Korean J Transplant; 2020 Mar; 34(1):24-30. PubMed ID: 35770260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics and dosage optimisation of tacrolimus coadministration with Wuzhi capsule in adult liver transplant patients.
    Du Y; Song W; Xiong X; Ge W; Zhu H
    Xenobiotica; 2022 Mar; 52(3):274-283. PubMed ID: 35502774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis.
    Buendia JA; Bramuglia G; Staatz CE
    Ther Drug Monit; 2014 Aug; 36(4):442-7. PubMed ID: 24378577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.